The use of botulinum toxin for the treatment of patients with overactive bladder

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.10.1002/nau.1005211857671Search in Google Scholar

2. Verghese TS, Middleton LJ, Daniels JP, Deeks JJ, Latthe PM. The impact of urodynamics on treatment and outcomes in women with an overactive bladder: a longitudinal prospective follow-up study. Int Urogynecol J 2018;29(4);513-9. doi: 10.1007/s00192-017-3414-4.10.1007/s00192-017-3414-4587627128721482Search in Google Scholar

3. Gulur DM, Drake MJ. Management of overactive bladder. Nat Rev Urol 2010;7(10):572-82.10.1038/nrurol.2010.14720930868Search in Google Scholar

4. Nowara A, Witek A. Naglący problem menopauzy. Prz Menopauz 2007;6:352-6.Search in Google Scholar

5. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(Suppl. 6):2455-63.10.1016/j.juro.2012.09.07923098785Search in Google Scholar

6. Arnold J, McLeod N, Thani-Gasalam R, Rashid P. Overactive bladder syndrome – management and treatment options. Aust Fam Physician 2012;41(11):878-83.Search in Google Scholar

7. Oskay UY, Beji NK, Yalcin O. A study on urogenital complaints of post-menopausal women aged 50 and over. Acta Obstet Gynecol Scand 2005;84(1):72-8.10.1111/j.0001-6349.2005.00645.x15603571Search in Google Scholar

8. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-36.10.1007/s00345-002-0301-412811491Search in Google Scholar

9. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87(9):760-6.10.1046/j.1464-410x.2001.02228.x11412210Search in Google Scholar

10. Sako T, Inoue M, Watanabe T, Ishii A, Yokoyama T, Kumon H. Impact of overactive bladder and lower urinary tract symptoms on sexual health in Japanese women. Int Urogynecol J 2011;22(2):165-9.10.1007/s00192-010-1250-x20798921Search in Google Scholar

11. Shin JH, Kim A, Choo MS. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy. Investig Clin Urol 2017;58(4):261-6.10.4111/icu.2017.58.4.261549435028681036Search in Google Scholar

12. Jankiewicz K, Kulik-Rechberger B, Nowakowski Ł, Rechberger T. Czynnik wzrostu nerwów (NGF) jako biomarker w diagnostyce i terapii pęcherza nadreaktywnego (OAB). Ginekol Pol 2012;83(7):532-6.Search in Google Scholar

13. Rechberger T, Kulik-Rechberger B, Miotła P, Wróbel A. Nowa era w farmakologicznym leczeniu pęcherza nadreaktywnego (OAB): mirabegron – selektywny agonista receptora β3. Ginekol Pol 2014;85(3):214-9.Search in Google Scholar

14. Bender S, Borowski J, Borkowski T, Torz C, Radziszewski P. Nietrzymanie moczu. Med Dypl 2011;20(6):73-80.Search in Google Scholar

15. Jabbari B. History of botulinum toxin treatment in movement disorders. Tremor Other Hyperkinet Mov (N Y) 2016;6:394.10.5334/tohm.321Search in Google Scholar

16. Drożdżyńska M, Sobieraj-Garbiak I, Chlasta A, Jastrzębska M. Toksyna botulinowa i i jej zastosowanie w medycynie. Diagn Lab 2015;51(2):139-46.10.5604/01.3001.0004.1521Search in Google Scholar

17. Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C, et al. The light chain defines the duration of action of botulinum toxin serotype A subtypes. MBio 2018;9(2). pii: e00089-18. doi: 10.1128/mBio.00089-18.10.1128/mBio.00089-18Search in Google Scholar

18. Zeino M, Becker T, Koen M, Berger C, Riccabona M. Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children. Cent European J Urol 2012;65(3):156-61.10.5173/ceju.2012.03.art12Search in Google Scholar

19. Jasiński M, Drewa T, Tyloch J, Wolski Z. Is botulinum toxin type a intrapro-static injections really effective in patients with urinary retention? Acta Pol Pharm 2011;68(5):765-8.Search in Google Scholar

20. Rechberger T, Wróbel A, Kokot M, Bartuzi A. Toksyna botulinowa – nowa opcja terapeutyczna w leczeniu zaburzeń czynnościowych pęcherza moczowego. Fam Med Primary Care Rev 2008;10(3):1040-4.Search in Google Scholar

21. Gardner AP, Barbieri JT. Light Chain Diversity among Botulinum Neurotoxins. Toxins (Basel) 2018;10(7). pii: E268. doi: 10.3390/toxins10070268.10.3390/toxins10070268Search in Google Scholar

22. Sławek J, Rudzińska M, editor. Toksyna botulinowa w praktyce neurologicznej. Gdańsk: Via Medica; 2015.Search in Google Scholar

23. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139(5):919-22.10.1016/S0022-5347(17)42717-0Search in Google Scholar

24. Rechberger T, Miotła P, Skorupski P, Wróbel A, Tomaszewski J. Jakość życia pacjentek z pęcherzem nadreaktywnym po zastosowaniu toksyny botulinowej – doniesienie wstępne. Ginekol Pol 2010;81:24-30.Search in Google Scholar

25. Eldred-Evans D, Dasgupta P. Use of botulinum toxin for voiding dysfunction. Transl Androl Urol 2017;6(2):234-51.10.21037/tau.2016.12.05542267628540231Search in Google Scholar

26. Denys P, Dmochowski R, Aliotta P, Castro-Diaz D, Blok B, Ethans K, et al. Positive outcomes with first onabotulinumtoxinA treatment persist in the long term with repeat treatments in patients with neurogenic detrusor overactivity. BJU Int 2017;119(6):926-32.10.1111/bju.1379528139068Search in Google Scholar

27. Eldred-Evans D, Sahai A. Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol 2017;9(1):3-10.10.1177/1756287216672180516707228042308Search in Google Scholar

28. Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013;111(1):106-13.10.1111/j.1464-410X.2012.11282.x22672569Search in Google Scholar

29. Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 2017;120(5):611-22.10.1111/bju.1394528670786Search in Google Scholar

30. Sherif H, Khalil M, Omar R. Management of refractory idiopathic over-active bladder: intradetrusor injection of botulinumtoxin type A versus posterior tibial nerve stimulation. Can J Urol 2017;24(3):8838-46.Search in Google Scholar

31. Ferreira RS, D’Ancona CAL, Oelke M, Carneiro MR. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. Einstein (Sao Paulo) 2018;16(3):eAO4207.10.1590/s1679-45082018ao4207Search in Google Scholar

32. Carneiro Neto JA, Santos SB, Orge GO, Tanajura D, Passos L, Oliveira CJ, et al. Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. Braz J Infect Dis 2018;22(2):79-84.10.1016/j.bjid.2017.10.00929462596Search in Google Scholar

33. Mühlstädt S, Mischner S, Kranz J, Anheuser P, Mohammed N, Steffens JA, et al. Quo vadis botulinum toxin: Normative constraints and quality of life for patients with idiopathic OAB?. Front Surg 2018; 5:61.10.3389/fsurg.2018.00061619808530386782Search in Google Scholar